Rochem Partner Marks Key Achievement

We are excited to announce Rochem International Inc. and our strategic partner Shenzhen JY MED have successfully received the EU GMP equivalent Written Confirmation (WC) for Liraglutide API, marking another key achievement towards commercialization.  This comes after having completed a successful US FDA inspection earlier in 2024 and confirms the readiness of Shenzhen JY MED and Rochem to support your needs for Liraglutide API.

Congratulations to our staff, and that of our strategic partner Shenzhen JY Med, on this accomplishment.  As the Exclusive Agent for Liraglutide API and others, we look forward to discussing this and other GLP-1 API needs you may have.